Daily Market Alert for US LEC Corp.

0 Comments | M2 Presswire, February, 2007

M2 PRESSWIRE-26 February 2007-Biotech News: Daily Market Alert for US LEC Corp.(C)1994-2007 M2 COMMUNICATIONS LTD RDATE:26022007 Iko iko unday! Icagen wants to set the market for ion channel modulators on fire. The development-stage biotech focuses on drugs to regulate the inflow of such ions as calcium, potassium, and sodium into cells to treat sickle cell disease, epilepsy, dementia, and other diseases and conditions.

Its lead candidate, ICA-17043 for sickle cell anemia, is in Phase III trials and has both fast track and orphan drug status in the US. McNeil Consumer & Specialty Pharmaceuticals is helping develop the drug and will co-promote it in the US upon FDA approval. Partner Bristol-Myers Squibb is developing one of Icagen's candidates to treat atrial...